2 models fit Veracyte Inc. Common Stock and they disagree: 0 of 2 land within 15% of the average. The price is above every model.
Two or more of our models back this value.
Large premium(i)Bronze56
Valued as a growth company: Discounted cash flow, P/E comparison, and EV/EBITDA comparison.
ACCE opinionVeracyte Inc. Common Stock (VCYT)
Fair value (2 models)
$29.77
ACCE price target
$48.00
Rating
Overvalued
Horizon
12 months
Fair value published on 10 Oct 2026, 00:00 CEST; previously $26.22 since 4 Oct 2026, 00:00 CEST.
ACCE price target published on 11 Oct 2026, 00:00 CEST.
Rating published on 19 Oct 2026, 17:05 CEST.
Price used: $47.93 at the close on 23 Oct 2026, 22:00 CEST.
Models: Discounted cash flow, EV/EBITDA comparison, and P/E comparison.
Fair value: the average of the applicable valuation models (discounted cash flow, multiples, residual income, dividend discount, shareholder yield), each run on the latest financial statements and the market price shown. Opinion columns (fair value, target, rating) are shown apart from the data. Full methodology: acceinvestments.com/data/how-we-value-stocks
Conflicts of interest: The author holds no personal position in this security. General statement
Produced by ACCE Investments (acceinvestments.com)
Data
Price vs fair value
61.0% above
-37.9% to fair value
ACCE score
74
out of 100
Analysts
85% buy
13 covering
P/E
32.9x
forward 23.6x
1-year return
+34.5%
Dividend yield
0.00%
Veracyte Inc. Common Stock in four questions
Plain answers, details below
Free accounts get 5 full stock pages a month, including the four answers.
Overview
ACCE thesis
Veracyte sells genomic diagnostic tests, most notably the Afirma thyroid nodule tests that help clinicians decide whether a biopsy is needed, plus the Decipher prostate and Percepta lung tests used in cancer treatment decisions. The moat is clinical: these tests are reimbursed, embedded in physician workflows, and backed by published validation data, which makes them hard to displace. Revenue growth of 15.5% and a 73.8% gross margin show that the franchise is scaling without giving up pricing. Operating margin of 15.3% is still modest, so the thesis rests on continued operating leverage as volume grows through the fixed cost base. At a trailing P/E of 30.8 and a forward P/E of 23.6, the market is pricing in earnings expansion, which makes the next few quarters of margin progression the key test.
⚠ Investor warnings · 1 flagAI-assisted·How I use AI
moderate
Elevated short interest
Short interest stands at 15.0% of the float. That is high enough to amplify moves in either direction, so position sizing should reflect the volatility it can bring.
AI research notes
AI-assisted·How I use AIWritten Oct 13, 2026 · figures from 2026-06-30 · prices to Oct 23, 2026
Why it could do well
Free cash flow of $127M over the last twelve months shows the business generates real cash, not just accounting profit.
The latest quarter beat expectations, with earnings per share of 0.37 against 0.29 expected, a surprise of +27.6%.
Why it could disappoint
The consensus fair value of $29.85 sits 32.2% below the $44.02 share price, suggesting the stock looks expensive on its own models.
Return on invested capital of 4.0% is thin, meaning the company earns little on the money put into the business.
Revenue growth slowed to +15.5% year over year, well below the 5-year average of +34.5% per year.
Each chip shows the exact figure and where it comes from. A claim without a source is not published.
Next results
Nov 4, 2026
We update the fair value about 2 days after the results, once the new figures are filed.Add to calendarGoogle
Walk me through this stock
Plain-English pros, cons, and what to watch. Pro feature.
PRO
Ask ACCE
Valuation
INVESTOR
Where VCYT's valuation models land
Price
$47.93
Model fair value
$29.77
Model range
$16.13 to $46.14
Fair value $29.77
Price $47.93
The price is above the whole model range.
Model
Fair value
Upside
Discounted cash flow
EV/EBITDA comparison
P/E comparison
Create a free account: 5 full stock pages a month, no card.
See what each model says, the assumptions behind it, the bad, normal and good cases, and why the fair value changed.
Quality
INVESTOR
Quality and conviction INVESTOR FEATURE
The full quality picture: a reason under every score, how the scores moved, and the conviction breakdown.
+A plain reason under every score
+Conviction breakdown and growth / value / quality / momentum scores